@article{5d8d9e43988a4ebc8daa06947b36bff5,
title = "SDF-1 is an autocrine insulin-Desensitizing factor in adipocytes",
abstract = "Insulin desensitization occurs not only under the obese diabetic condition but also in the fasting state. However, little is known about the common secretory factor(s) that are regulated under these two insulin-desensitized conditions. Here, using database analysis and in vitro and in vivo experiments, we identified stromal derived factor-1 (SDF-1) as an insulin-desensitizing factor in adipocytes, overexpressed in both fasting and obese adipose tissues. Exogenously added SDF-1 induced extracellular signal–regulated kinase signal, which phosphorylated and degraded IRS-1 protein in adipocytes, decreasing insulin-mediated signaling and glucose uptake. In contrast, knockdown of endogenous SDF-1 or inhibition of its receptor in adipocytes markedly increased IRS-1 protein levels and enhanced insulin sensitivity, indicating the autocrine action of SDF-1. In agreement with these findings, adipocyte-specific ablation of SDF-1 enhanced insulin sensitivity in adipose tissues and in the whole body. These results point to a novel regulatory mechanism of insulin sensitivity mediated by adipose autocrine SDF-1 action and provide a new insight into the process of insulin desensitization in adipocytes.",
author = "Jihoon Shin and Atsunori Fukuhara and Toshiharu Onodera and Shunbun Kita and Chieko Yokoyama and Michio Otsuki and Iichiro Shimomura",
note = "Funding Information: This work was partly supported by the Japan Society for the Promotion of Science Grant-in-aid for Scientific Research (C) (grant no. 17K09829), and the Osaka University Institute for Academic Initiatives. J.S. is supported by a Japanese Government Ministry of Education, Culture, Sports, Science and Technology scholarship. Funding Information: Acknowledgments. The authors thank all members of the Shimomura Laboratory, Interdisciplinary Program for Biomedical Sciences (IPBS), T. Nagasawa and T. Sugiyama (Laboratory of Stem Cell Biology and Developmental Immunology, Graduate School of Frontier Biosciences, Osaka University) for the helpful discussion, E. Rosen (Department of Genetics, Harvard Medical School) and J. Eguchi (Division of Nephrology, Diabetology and Endocrinology, Okayama University) for providing adiponectin-Cre, and J. Zimmermann and T. Hunter (Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies) for providing pcDNA3-mIRS-1 vectors. Funding. This work was partly supported by the Japan Society for the Promotion of Science Grant-in-aid for Scientific Research (C) (grant no. 17K09829), and the Osaka University Institute for Academic Initiatives. J.S. is supported by a Japanese Government Ministry of Education, Culture, Sports, Science and Technology scholarship. Duality of Interest. This work was partially supported by Sanofi (grant), AstraZeneca (grant), and Merck Sharp & Dohme (grant). A.F. and S.K. belong to a department endowed by Takeda Pharmaceutical Company; Sanwa Kagaku Ken-kyusho Co., Ltd.; Rohto Pharmaceutical Co., Ltd.; Fuji Oil Holdings Inc.; and Roche DC Japan. Publisher Copyright: {\textcopyright} 2018 by the American Diabetes Association.",
year = "2018",
month = jun,
day = "1",
doi = "10.2337/db17-0706",
language = "English (US)",
volume = "67",
pages = "1068--1078",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "6",
}